• Axel Schmidt, Ana M Groh, Julia S Frick, VehreschildMaria J G TMJGT, and Kerstin U Ludwig.
• Institute of Human Genetics, Medical Faculty of the University of Bonn & Bonn; University Hospital Medical Department II, Infectiology, University Hospital-Frankfurt, Goethe; University Frankfurt Interfaculty Institute for Microbiology and Infection Medicine, University Hospital and Faculty of Medicine Tübingen; MVZ Laboratory Ludwigsburg GbR.
• Dtsch Arztebl Int. 2022 Feb 25; 119 (8): 117-123.

BackgroundContact with a pathogen is followed by variable courses of infectious disease, which are only partly explicable by classical risk factors. The susceptibility to infection is variable, as is the course of disease after infection. In this review, we discuss the extent to which this variation is due to genetic factors of the affected individual (the host).MethodsSelective review of the literature on host genetics in infectious disease, with special attention to the pathogens SARSCoV- 2, influenza viruses, Mycobacterium tuberculosis, and human immunodeficiency virus (HIV).ResultsGenetic variants of the host contribute to the pathogenesis of infectious diseases. For example, in HIV infection, a relatively common variant leading to a loss of function of the HIV co-receptor CCR5 affects the course of the disease, as do variants in genes of the major histocompatibility complex (MHC) region. Rare monogenic variants of the interferon immune response system contribute to severe disease courses in COVID-19 and influenza (type I interferon in these two cases) and in tuberculosis (type II interferon). An estimated 1.8% of life-threatening courses of COVID-19 in men under age 60 are caused by a deficiency of toll-like receptor 7. The scientific understanding of host genetic factors has already been beneficial to the development of effective drugs. In a small number of cases, genetic information has also been used for individual therapeutic decision-making and for the identification of persons at elevated risk.ConclusionA comprehensive understanding of host genetics can improve the care of patients with infectious diseases. Until the present, the clinical utility of host genetics has been limited to rare cases; in the future, polygenic risk scores summarizing the relevant genetic variants in each patient will enable a wider benefit. To make this possible, multicenter studies are needed that will systematically integrate clinical and genetic data.

22 keywords...

hide…